Singapore Pulmonary Embolism Therapeutics Market Size & Outlook, 2026-2034
Singapore Pulmonary Embolism Therapeutics Market Insights
- According to Reed Intelligence analysis, the Singapore Pulmonary Embolism Therapeutics Market size was USD 13.12 Million in 2025 and is projected to reach USD 27.81 Million by 2034.
- The Singapore market is projected to grow at a CAGR of 8.61% between 2026 and 2034.
- By segment, Anticoagulants emerged as the largest Drug Class in terms of market size in 2025.
- Anticoagulants is anticipated to remain the most attractive Drug Class segment, recording the fastest growth during the forecast period.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2025, Singapore represented 0.35% of the overall global Pulmonary Embolism Therapeutics Market size.
- United States is projected to lead the global Pulmonary Embolism Therapeutics Market size by 2034.
- Across Asia Pacific, China is anticipated to hold the dominant position in market size by 2034.
- Japan is forecasted to expand at the fastest pace in Asia Pacific, attaining USD 192.99 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 13.12 Million |
| Market Size In 2034 | USD 27.81 Million |
| Largest segment | Anticoagulants |
| Units | Revenue in USD Million |
| CAGR | 8.61% (2026-2034) |
| Segmnetation Covered | |
| Drug Class |
|
| Route of Administration |
|
| End-Use |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Singapore Pulmonary Embolism Therapeutics Market Drug Class 2026-2034 (USD Million)
| Drug Class | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anticoagulants | XX.x | XX.x | XX.x | 6.8 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Thrombolytics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Singapore Pulmonary Embolism Therapeutics Market Route of Administration 2026-2034 (USD Million)
| Route of Administration | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oral | XX.x | XX.x | XX.x | 8.34 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Injectable | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Singapore Pulmonary Embolism Therapeutics Market End-Use 2026-2034 (USD Million)
| End-Use | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | XX.x | XX.x | XX.x | 5.9 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Ambulatory Surgical Centers | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Specialty Clinics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
